P. Dragovich

发表

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine.

T. Hermann, C. Kissinger, Qiang Zhao, 2008, Bioorganic & medicinal chemistry letters.

Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.

D. Sampath, P. Dragovich, T. O'Brien, 2015, Toxicological sciences : an official journal of the Society of Toxicology.

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Karl H. Clodfelter, P. Bauer, N. Kley, 2013, Bioorganic & medicinal chemistry letters.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Bo Liu, Rose Ann Ferre, Tove Tuntland, 2002, Journal of medicinal chemistry.

Regiospecific synthesis of 1,5-disubstituted-1H-pyrazoles containing differentiated 3,4-dicarboxylic acid esters via Suzuki coupling of the corresponding 5-trifluoromethane sulfonates

Yuefen Zhou, D. Murphy, Lian-Sheng Li, 2007 .

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα).

C. Li, R. Rowntree, BinQing Wei, 2019, Bioorganic & medicinal chemistry letters.

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

M. Hickey, J. Thomson, P. Dragovich, 2003, Journal of Virology.

Studies on the thermal generation and reactivity of a class of (.sigma.,.pi.)-1,4-biradicals

Andrew G. Myers, P. Dragovich, A. Myers, 1992 .

Studies on the Thermal Generation and Reactivity of a Class of (σ ,π)-1,4-Biradicals.

P. Dragovich, A. Myers, E. Y. Kuo, 1993 .

Calicheamicin Antibody–Drug Conjugates with Improved Properties

B. Vollmar, A. Kamath, P. Dragovich, 2021, Molecular Cancer Therapeutics.

Antibody Drug Conjugates Differentiate Uptake and DNA Alkylation of Pyrrolobenzodiazepines in Tumors from Organs of Xenograft Mice

Hong Wang, P. Dragovich, C. Hop, 2016, Drug Metabolism and Disposition.

Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes

P. Dragovich, Donglu Zhang, Thomas H. Pillow, 2019, Drug Metabolism and Disposition.

Improved translation of stability for conjugated antibodies using an in vitro whole blood assay

Yichin Liu, P. Dragovich, J. C. Tran, 2020, mAbs.

Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues

P. Dragovich, C. Hop, Donglu Zhang, 2019, Drug Metabolism and Disposition.

Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates

P. Dragovich, C. Hop, Donglu Zhang, 2018, Molecular Cancer Therapeutics.

Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.

R. Rowntree, James Lee, D. Stokoe, 2018, Molecular pharmaceutics.

Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates

P. Dragovich, C. Hop, H. Erickson, 2016, Drug Metabolism and Disposition.

Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo.

Jeffrey T. Lau, R. Rowntree, B. Vollmar, 2019, Bioconjugate chemistry.

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

Melinda M. Mulvihill, Karen E Gascoigne, R. Rowntree, 2020, ChemMedChem.

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2013, Journal of medicinal chemistry.

Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

R. Rowntree, D. Seshasayee, R. Vij, 2020, mAbs.

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Leslie B. Lee, D. Sampath, P. Jackson, 2013, Neoplasia.

Versatile Precursors for the Synthesis of Enynes and Enediynes

M. Fuhry, P. Dragovich, M. Alauddin, 1989 .

Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor

D. Sampath, P. Dragovich, B. Liederer, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines

A. Bruening-Wright, D. Sampath, P. Dragovich, 2017, Cardiovascular Toxicology.

Antibody-Drug Conjugates for Immunology.

P. Dragovich, 2022, Journal of medicinal chemistry.

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

X. Chen, T. Januario, M. Merchant, 2022, Nature Communications.

Degrader-antibody conjugates.

P. Dragovich, 2022, Chemical Society reviews.

Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.

P. A. Thompson, J. Khandurina, C. Kissinger, 2009, Bioorganic & medicinal chemistry letters.

Inhibition of Human Rhinovirus-Induced Cytokine Production by AG7088, a Human Rhinovirus 3C Protease Inhibitor

P. Dragovich, S. Worland, M. A. Brothers, 2000, Antimicrobial Agents and Chemotherapy.

An optical thin film assay incorporating rhinovirus protease inhibitors as detector reagents.

B. Polisky, P. Dragovich, S. Worland, 2004, Antiviral research.

Recent advances in the development of human rhinovirus 3C protease inhibitors

P. Dragovich, 2001 .

Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides.

P. Dragovich, S. Worland, J. Meador, 1999, Bioorganic & medicinal chemistry.

Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.

Jingjing Zhao, Matthew A. Lardy, Frank Ruebsam, 2008, Bioorganic & medicinal chemistry letters.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

D. Matthews, P. Rejto, P. W. Rose, 2003, Journal of medicinal chemistry.

In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease

D. Matthews, M. Diem, P. Dragovich, 1999, Antimicrobial Agents and Chemotherapy.

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

D. Matthews, T. Hendrickson, S. Webber, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.

D. Matthews, S. Webber, P. Dragovich, 1999, Bioorganic & medicinal chemistry letters.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

D. Matthews, P. Rejto, T. Hendrickson, 1999, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

D. Matthews, P. Dragovich, R. Ferre, 1999, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.

D. Matthews, R. Babine, S. Webber, 1998, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

D. Matthews, R. Babine, S. Webber, 1998, Journal of medicinal chemistry.

A regioselective synthesis of pyrroles via the coupling of .alpha.,.beta.-unsaturated imines with esters or N,N-dimethylformamide promoted by NbCl3(DME)

P. Dragovich, S. F. Pedersen, J. Hartung, 1989 .

Design and Synthesis of a System for Enediyne Formation by Anthraquinone Reductive Activation

P. Dragovich, A. Myers, 1992 .

Structure-based design of novel, urea-containing FKBP12 inhibitors.

D. Knighton, C. Kissinger, J. E. Villafranca, 1996, Journal of medicinal chemistry.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.

C. Kissinger, Qing Han, Michael Noble, 2008, Bioorganic & medicinal chemistry letters.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Rose Ann Ferre, D. Matthews, P. Dragovich, 2002, Bioorganic & medicinal chemistry letters.

Synthesis of an optically active, bicyclic 2-pyridone dipeptide mimetic.

P. Dragovich, T. Prins, R. Zhou, 2002, The Journal of organic chemistry.

5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.

Yuefen Zhou, S. Webber, D. Murphy, 2009, Bioorganic & medicinal chemistry letters.

Efficient synthesis of (1R,2S) and (1S,2R)-2-aminocyclopentanecarboxylic acid ethyl ester derivatives in enantiomerically pure form

Yuefen Zhou, D. Murphy, Lian-Sheng Li, 2008 .

Niobium(III) and (IV) Halide Complexes

P. Dragovich, S. F. Pedersen, J. Hartung, 2007 .

A Regioselective Synthesis of Pyrroles (III) via the Coupling of α,β-Unsaturated Imines (I) with Esters (IIb), (IIc) or N,N-Dimethylformamide (IIa) Promoted by NbCl3(DME).

P. Dragovich, S. F. Pedersen, J. Hartung, 1990 .

Synthesis and characterization of stoichiometric CdPS3

P. Dragovich, R. Kubin, J. Covino, 1985 .

A Novel Depurination Methodology to Assess DNA Alkylation of Chloro-Bis-Seco-Cyclopropylbenzoindoles Allowed for Comparison of Minor-Groove Reactivity

BinQing Wei, P. Dragovich, C. Khojasteh, 2019, Drug Metabolism and Disposition.

Palladium Catalyzed, Regioselective Reduction of 1,2-Epoxides by Ammonium Formate

P. Dragovich, T. Prins, R. Zhou, 1995 .

Efficient synthesis of 2,6-disubstituted-5-hydroxy-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid ethyl esters

Yuefen Zhou, D. Murphy, Lian-Sheng Li, 2008 .

Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase

Xukun Chen, Mark Zak, Yongbo Liu, 2014, Chembiochem : a European journal of chemical biology.

Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.

Karl H. Clodfelter, Zhongguo Wang, Mark Zak, 2013, Journal of medicinal chemistry.

A reaction cascade leading to 1,6-didehydro[10]annulene .fwdarw. 1,5-dehydronaphthalene cyclization initiated by thiol addition

P. Dragovich, A. Myers, 1993 .

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.

D. Matthews, S. Webber, P. Dragovich, 2000, Bioorganic & medicinal chemistry letters.

Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice.

Marie Evangelista, BinQing Wei, M. Ultsch, 2016, ACS medicinal chemistry letters.

Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2014, Bioorganic & medicinal chemistry letters.

Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2015, Bioorganic & medicinal chemistry letters.

Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2014, Bioorganic & medicinal chemistry letters.

Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2013, Bioorganic & medicinal chemistry letters.

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.

Deepak Sampath, Tanja S. Zabka, D. Sampath, 2015, Pharmacology & therapeutics.

Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Ignacio Aliagas, 2013, Journal of medicinal chemistry.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Tian Jin, 2012, Journal of medicinal chemistry.

Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors

M. Volgraf, A. Rohou, C. Arthur, 2022, bioRxiv.

Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2013, Bioorganic & medicinal chemistry letters.

Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.

Jun Liang, P. Trojer, R. Cummings, 2016, Bioorganic & medicinal chemistry letters.

From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

Jun Liang, P. Trojer, Y. Ran, 2017, Bioorganic & medicinal chemistry letters.

Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.

Jun Liang, P. Trojer, R. Cummings, 2016, Bioorganic & medicinal chemistry letters.

Design and dynamics of a chemically triggered reaction cascade leading to biradical formation at subambient temperature

P. Dragovich, A. Myers, 1989 .

Design and Dynamics of a Chemically Triggered Reaction Cascade Leading to Biradical Formation at Subambient Temperature.

P. Dragovich, A. Myers, 1990 .

Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors.

Hui Li, M. Hickey, P. Dragovich, 2006, Bioorganic & medicinal chemistry letters.

The crystal structure of the RNA-dependent RNA polymerase from human rhinovirus: a dual function target for common cold antiviral therapy.

P. Dragovich, H. Parge, R. Ferre, 2004, Structure.

Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.

Yang Xiao, Lei Zhang, Karl H. Clodfelter, 2013, Bioorganic & medicinal chemistry letters.

Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.

N. Skelton, D. Sampath, K. Bair, 2016, Journal of medicinal chemistry.

Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.

Karl H. Clodfelter, N. Skelton, D. Sampath, 2015, Bioorganic & medicinal chemistry letters.

Measuring NAD(+) levels in mouse blood and tissue samples via a surrogate matrix approach using LC-MS/MS.

P. Dragovich, B. Liederer, C. Hop, 2014, Bioanalysis.

IN VITRO ANTIVIRAL ACTIVITY OF HUMAN RHINOVIRUS 3C PROTEASE INHIBITORS AGAINST THE SARS CORONAVIRUS

D. Matthews, P. Rejto, P. W. Rose, 2004 .

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

Robert A. Love, Xiu Yu, Hans E. Parge, 2003, Journal of Virology.

Efficient Large-Scale Synthesis of 2-Amino-5-methanesulfonylaminobenzenesulfonamide

D. Murphy, P. Dragovich, Chinh Tran, 2008 .

4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.

Matthew A. Lardy, C. Kissinger, Qing Han, 2008, Bioorganic & medicinal chemistry letters.

Efficient Large‐Scale Synthesis of 2‐Amino‐5‐methanesulfonylaminobenzenesulfonamide.

D. Murphy, P. Dragovich, Chinh Tran, 2008 .

Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody–Drug Conjugates

Liling Liu, Yichin Liu, P. Dragovich, 2019, Drug Metabolism and Disposition.

Synthesis of New Pyridazinone Derivatives: 2,6-Disubstituted 5-Hydroxy-3(2H)-pyridazinone-4-carboxylic Acid Ethyl Esters

Yuefen Zhou, S. Webber, D. Murphy, 2007 .

Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Yang Xiao, Lei Zhang, Deepak Sampath, 2013, Bioorganic & medicinal chemistry letters.

Systematic Variation of Pyrrolobenzodiazepine (PBD)-dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.

R. Rowntree, BinQing Wei, P. Dragovich, 2020, Journal of medicinal chemistry.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Charles Eigenbrot, 2012, Bioorganic & medicinal chemistry letters.

Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.

Karl H. Clodfelter, Zhongguo Wang, Mark Zak, 2013, Bioorganic & medicinal chemistry letters.

Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.

Karl H. Clodfelter, P. Bauer, N. Kley, 2013, Journal of medicinal chemistry.

Structure-based Optimization of Hydroxylactam as Potent, Cell-Active Inhibitors of Lactate Dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2022, Bioorganic & medicinal chemistry letters.

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.

Melinda M. Mulvihill, Karen E Gascoigne, R. Rowntree, 2021, Journal of medicinal chemistry.

Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid

Dolores Diaz, Deepak Sampath, Hirdesh Uppal, 2015, Toxicology mechanisms and methods.

Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors

D. Sampath, K. Bair, Weiru Wang, 2014, PloS one.

Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2014, Bioorganic & medicinal chemistry letters.

Small-Molecule Lead-Finding Trends across the Roche and Genentech Research Organizations.

Melinda M. Mulvihill, W. Haap, A. Stepan, 2022, Journal of medicinal chemistry.

An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models

R. Rowntree, P. Dragovich, Fiona Zhong, 2020, Molecular Cancer Therapeutics.

Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs.

P. Dragovich, F. Broccatelli, J. Wai, 2017, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.

C. Kissinger, Qiang Zhao, Yuefen Zhou, 2008, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.

Matthew A. Lardy, Yuefen Zhou, S. Webber, 2008, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituents.

T. Hermann, C. Kissinger, Qiang Zhao, 2008, Bioorganic & medicinal chemistry letters.

Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates.

P. Dragovich, C. Hop, J. Wai, 2016, ACS medicinal chemistry letters.

Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody-Drug Conjugates with Phenol-Containing Payloads.

B. Vollmar, BinQing Wei, P. Dragovich, 2018, Bioconjugate chemistry.

Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.

D. Matthews, B. Srinivasan, S. Webber, 2001, Bioorganic & medicinal chemistry letters.

Spectroscopic and crystallographic characterization of (σ2-terpyridyl)Re(CO)3Cl. 2D-NMR evidence for a linkage isomerization reaction

P. Dragovich, T. Karpishin, T. D. Westmoreland, 1993 .

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.

Melinda M. Mulvihill, R. Rowntree, Wentao Wei, 2021, Journal of medicinal chemistry.

Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker.

R. Rowntree, B. Vollmar, I. Wertz, 2018, Chemistry.

Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs

P. Dragovich, F. Broccatelli, Donglu Zhang, 2023, Pharmaceutics.

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.

D. Sampath, P. Dragovich, T. O'Brien, 2015, Pharmacology & therapeutics.

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2013, Journal of medicinal chemistry.

is not an appropriate payload of antibody-drug conjugates as rapid inactivation by lysosomal enzymes

P. Dragovich, Thomas H. Pillow, Josefa dela Cruz-Chuh, 2019 .

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Adam R. Johnson, Rohan V Mendonca, M. Ultsch, 2012, Bioorganic & medicinal chemistry letters.